THIRD HARMONIC BIO INC (THRD) Stock Price, Quote, News and Overview
NASDAQ:THRD - Nasdaq - US88427A1079 - Common Stock - Currency: USD
THRD Quote, Performance and Key Statistics
THIRD HARMONIC BIO INC
NASDAQ:THRD (2/11/2025, 6:10:32 PM)
After market: 3.3 +0.05 (+1.54%)3.25
-1.4 (-30.11%)
The current stock price of THRD is 3.25 USD. In the past month the price decreased by -50.15%. In the past year, price decreased by -67.73%.
THRD Latest News and Analysis
Tuesday's session: top gainers and losers
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Tuesday's session: gap up and gap down stocks
Let's have a look at the gap up and gap down stocks in today's session.
Which stocks are moving before the opening bell on Tuesday?
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
THRD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.54 | 821.16B | ||
| JNJ | JOHNSON & JOHNSON | 15.63 | 375.90B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.5 | 371.82B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.15 | 225.54B | ||
| MRK | MERCK & CO. INC. | 11.33 | 218.92B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.74 | 215.42B | ||
| PFE | PFIZER INC | 8.21 | 144.68B | ||
| SNY | SANOFI-ADR | 13.61 | 135.14B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 49.07 | 113.46B | ||
| ZTS | ZOETIS INC | 30.26 | 78.63B | ||
| GSK | GSK PLC-SPON ADR | 7.82 | 73.59B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.55 | 42.61B |
Related stock screener links
About THRD
Company Profile
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 51 full-time employees. The company went IPO on 2022-09-15. The firm is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. The company is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The firm is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
Company Info
THIRD HARMONIC BIO INC
1700 Montgomery Street, Suite 210
San Francisco CALIFORNIA US
Employees: 42
Company Website: https://thirdharmonicbio.com/
Investor Relations: https://ir.thirdharmonicbio.com/
Phone: 12097272457
THRD FAQ
What is the stock price of THRD?
The current stock price of THRD is 3.25 USD.
What is the symbol for THIRD HARMONIC BIO INC stock?
The exchange symbol of THIRD HARMONIC BIO INC is THRD and it is listed on the Nasdaq exchange.
On which exchange is THRD stock listed?
THRD stock is listed on the Nasdaq exchange.
Is THRD a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for THRD, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of THRD.
Does THRD stock pay dividends?
THRD does not pay a dividend.
What is the Price/Earnings (PE) ratio of THRD?
THRD does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).
What is the Short Interest ratio of THRD stock?
The outstanding short interest for THRD is 10.92% of its float.
THRD Technical Analysis
THRD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THRD. No worries on liquidiy or solvency for THRD as it has an excellent financial health rating, but there are worries on the profitability.
THRD Financial Highlights
Over the last trailing twelve months THRD reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS decreased by 15.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.87% | ||
| ROE | -13.29% | ||
| Debt/Equity | 0 |
THRD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to THRD. The Buy consensus is the average rating of analysts ratings from 12 analysts.